Literature DB >> 11489553

Solubilization of NSC-639829.

N Jain1, G Yang, S E Tabibi, S H Yalkowsky.   

Abstract

Solubilization using pH combined with cosolvents, surfactants, and complexants are investigated for NSC-639829, an investigational anti-tumor agent. The intrinsic solubility of the drug is approximately 30 ng/ml and it has an ionizable dimethyl aniline group with an approximate base pK(a) of 5. Samples buffered at pH 1.0, 2.0, and 7.0 with various concentrations of the solubilizing agents were used to study the solubilization of NSC-629829 when present as charged and uncharged species. The solubilization of NSC-639829 was found to be much more effective when the drug was present primarily in ionized form. At pH values 1.0 and 2.0 where the surfactant (SLS) and complexant (SBEbetaCD) carried a negative charge enhanced solubilities of more than a million-fold were observed for the drug.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11489553     DOI: 10.1016/s0378-5173(01)00773-6

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  3 in total

1.  Liposome formulation of NSC-639829 using halothane as a solvent: a technical note.

Authors:  Akash Jain; Tapan Sanghvi; Samuel H Yalkowsky
Journal:  AAPS PharmSciTech       Date:  2003-10-15       Impact factor: 3.246

2.  Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours.

Authors:  Wells A Messersmith; Michelle A Rudek; Sharyn D Baker; Ming Zhao; Connie Collins; A Dimitrios Colevas; Ross C Donehower; Michael A Carducci; Antonio C Wolff
Journal:  Eur J Cancer       Date:  2006-11-03       Impact factor: 9.162

3.  Application of the Solute-Solvent Intermolecular Interactions as Indicator of Caffeine Solubility in Aqueous Binary Aprotic and Proton Acceptor Solvents: Measurements and Quantum Chemistry Computations.

Authors:  Tomasz Jeliński; Maciej Kubsik; Piotr Cysewski
Journal:  Materials (Basel)       Date:  2022-03-27       Impact factor: 3.623

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.